Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: Role of interferon-γ in enhancement of surface expression of ICAM-1 on tumor cells in vivo

Clinical Immunology and Immunopathology

Volumn 78, Issue 3, 1996, Pages 283-290

  Kitsuki, Hisao ^a,c   Katano, Mitsuo ^b   Ikubo, Akashi ^c   Morisaki, Takashi ^c   Anann, Keisei ^c   Tanaka, Masao ^c   Torisu, Motomichi ^c  

^a TAKANO HOSPITAL   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; PICIBANIL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029942494     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0040     Document Type: Article

References (36)

1. Katano, M., and Torisu, M., Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50, 62-68, 1982.
2. Torisu, M., Katano, M., Kimura, Y., Itoh, H., and Takesue, M., New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93, 357-364, 1983.
3. Torisu, M., Sakata, M., Fujimura, T., et al., Successful treatment of malignant ascites: Clinical evaluation and role of host's inflammatory cells in tumor cell destruction in ascites. In "Basic Mechanisms and Clinical Treatment of Tumor Metastasis". (M. Torisu and T. Yosida, Eds.), pp. 593-615, Academic Press, London, 1985.
4. Katano, M., and Torisu, M., New approach to management of malignant ascites with a streptococcal preparation OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 93, 365-373, 1983.
5. Kawaguchi, T., Suematsu, M., Koizumi, H. M., et al., Activation of macrophage function by intraperitoneal administration of the streptococcal antitumor agent OK-432. Immunopharmacology 6, 177-189, 1983.
6. Uchida, A., and Micksche, M., Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. J. Natl Cancer Inst. 71, 673-680, 1983.
7. Hayashi, Y., and Torisu, M., New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils. Surgery 107, 74-84, 1990.
8. Sanchez-Madrid, F., Nagy, J., Robbins, E., Simon, P., and Springer, T. A., A human leukocyte differentiation antigen family with distinct alpha subunits and a common beta subunit: The lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor CR3 (OKM1/Mac-1), and the p150,95 molecule. J. Exp. Med. 158, 1785-1803, 1983.
9. Kishimoto, T. K., Larson, R. S., Corbi, A. L., et al., The leukocyte integrins. Adv. Immunol. 46, 149-182, 1989.
10. Springer, T. A., Adhesion receptors of the immune system. Nature 346, 425-434, 1990.
11. Marlin, S. D., and Springer, T. A., Purified intercellular adhesion molecule 1 (ICAM-1) is a ligand for lymphocyte functionassociated antigen 1 (LFA-1). Cell 51, 813-819, 1987.
12. Diamond, M. S., Stauton, D. E., de Fougerolles, A. R., et al., ICAM-1 (CD54): A counter-receptor for Mac-1 (CD11b/CD18). J. Cell Biol. 111, 3129-3139, 1990.
13. Billaud, M., Calender, A., Seigneurin, J. M., and Lenoir, G. M., LFA-1, LFA-3, and ICAM-1 expression in Burkitt's lymphoma. Lancet 2, 1327-1328, 1987.
14. Johnson, J. P., Stade, B. G., Holzmann, B., Schwable, W., and Riethmuller, G., De novo expression of intercellular adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc. Natl. Acad. Sci. USA 86, 641-644, 1989.
15. Vogetseder, W., Feichtinger, H., Schulz, T. F., et al., Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts. Int. J. Cancer 43, 768-773, 1989.
16. Makgoba, M. W., Sanders, M. E., Ginther Luce, G. E., et al., Functional evidence that intercellular adhesion molecule (ICAM-1) is a ligand for LFA-1 in cytotoxic T cell recognition. Eur. J. Immunol. 18, 637, 1988.
17. Webb, D. S. A., Mostowski, H. S., and Gerrard, T. L., Cytokine induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte mediated lysis. J. Immunol. 146, 3682-3686, 1991.
18. Kitsuki, H., Uchiyama, A., Yoshida, T., and Torisu, M., OK-432-induced enhancement of ICAM-1 expression on tumor cells positively correlates to therapeutic effects for malignant effusion. Clin. Immunol. Immunopathol. 71, 89-95, 1994.
19. Mortarni, R., Belli, F., Parmiani, G., et al., Cytokine mediated modulation of HLA-class 2, ICAM-1, LFA-3 and tumorassociated antigen profile of melanoma cells. Int. J. Cancer 45, 334-341, 1990.
20. Kuppner, M. C., Van Meir, E., Hamou, M. F., and De Tribolet, N., Cytokine regulation of intercellular adhesion molecule-1 (ICAM-1) expression on human glioblastoma cells. Clin. Exp. Immunol. 81, 142-148, 1990.
21. Tomita, Y., Nishiyama, T., Watanabe, H., Fujiwara, M., and Sato, S., Expression of intercellular adhesion molecule 1 (ICAM-1) on renal-cell cancer: Possible significance in host immune responses. Int. J. Cancer 46, 1001-1006, 1990.
22. Ichimura, O., Suzuki, S., Saito, M., Sugawara, Y., and Ishida, N., Augmentation of interleukin 1 and interleulin 2 production by OK-432. Int. J. Immunopharmacol. 7, 263-270, 1985.
23. Kokunai, I., Shimano, T., Sekimoto, K., et al., Induction of tumor necrosis factor by administration of OK-432 in cancer patients. J. Clin. Lab. Immunol. 21, 169-171, 1986.
24. Hoshino, T., Iho, S., Kura, F., and Uchida, A., In vivo and in vitro biological effects of OK-432, a streptococcal preparation, on the augmentation of autologous tumor cell killing activity and cytokine production of lymphocytes and monocytes in malignant diseases. In "A Biological Response Modifier" (M. Micksche and E. Klein, Eds.), pp. 61-68, Professional Postgraduate Services, Tokyo, 1986.
25. Tsuchiya, I., Kasahara, T., Yamashita, K., et al., Induction of inflammatory cytokines in the pleural effusion of cancer patients after the administration of an immunomodulator, OK-432: Role of IL-8 for neutrophil infiltration. Cytokine 5, 595-603, 1993.
26. Okamoto, H., Shoin, S., Koshimura, S., and Shimizu, R., Studies on the anti cancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn. J. Microbiol. 11, 323-336, 1973.
27. Yamaue, H., Tanimura, H., Tsunoda, T., et al., Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur. J. Cancer 27, 1263-1268, 1991.
28. Das, K. M., Squillante, L., and Robertson, F. M., Amplified expression of intercellular adhesion molecule-1 (ICAM-1) and M (r) 40k protein by DLD-1 colon tumor cells by interferon-gamma. Cell Immunol. 147, 215-221, 1993.
29. Hansen, A. B., Bouchelouche, P. N., Lillevang, S. T., and Andersen, C. B., Interferon-gamma increases cellular calcium ion concentration and inositol 1,4,5-trisphosphate formation in human renal carcinoma cells: Relation to ICAM-1 antigen expression. Br. J. Cancer 69, 291-298, 1994.
30. Morisaki, T., and Torisu, M., Enhanced adherence activity of OK-432-induced peritoneal neutrophils to tumor cells correlates to their increased expression of CD11b/CD18. Clin. Immunol. Immunopathol. 59, 474-486, 1991.
31. Riviere, Y., and Hovanessian, A. G., Direct action of interferon and inducers of interferon on tumor cells in athymic nude mice. Cancer Res. 43, 4596-4599, 1983.
32. Carrel, S., Schmidt-Kessen, A., and Giuffre, L., Recombinant interferon-γ can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur. J. Immunol. 15, 118-123, 1985.
33. Saito, T., Berens, M. E., and Welander, C. E., Direct and indirect effects of human recombinant γ-interferon on tumor cells in a clonogenic assay. Cancer Res. 46, 1142-1147, 1986.
34. Frey, J. R., Kamber, M., and Peck, R., Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells. Lymphokine Res. 6, 215-227, 1987.
35. D'Acquist, R., Markman, M., Hakes, T., Rubin, S., Hoskins, W., and Lewis, J. L. Jr., A phase I trial of intraperitoneal recombinant γ-interferon in advanced ovarian carcinoma. J. Clin. Oncol. 6, 689-695, 1988.
36. Allavena, P., Peccatori, F., Maggioni, D., et al., Intraperitoneal recombinant γ-interferon in patients with recurrent ascitic ovarian carcinoma: Modulation of cytotoxicity and cytokine production in tumor-associated effectors and major histocompatibility antigen expression on tumor cells. Cancer Res. 50, 7318-7323, 1990.